APOP
Income statement / Annual
Last year (2019), Cellect Biotechnology Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2019, Cellect Biotechnology Ltd.'s net income was $16.81 M.
See Cellect Biotechnology Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$12.12 M
|
$13.51 M
|
$11.50 M
|
$8.26 M
|
| General & Administrative
Expenses |
$10.21 M
|
$15.73 M
|
$12.93 M
|
$7.97 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.21 M
|
$15.73 M
|
$12.93 M
|
$7.97 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
-$280,000.00 |
| Operating Expenses |
$22.33 M |
$29.25 M |
$24.43 M |
$15.94 M |
| Cost And Expenses |
$22.33 M |
$29.25 M |
$24.43 M |
$15.94 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$433,000.00
|
$459,000.00
|
$372,000.00
|
$350,000.00
|
| EBITDA |
$17.24 M
|
$459,000.00
|
$28.60 M
|
$15.67 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
$16.81 M |
$0.00 |
$28.22 M |
$15.32 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Net Income |
$16.81 M |
$0.00 |
$28.22 M |
$15.32 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
| EPS |
0.32 |
0 |
1.01 |
0.67 |
| EPS Diluted |
0.32 |
0 |
1.01 |
0.67 |
| Weighted Average Shares
Out |
$53.16 M
|
$32.36 M
|
$27.99 M
|
$22.78 M
|
| Weighted Average Shares
Out Diluted |
$53.16 M
|
$32.36 M
|
$27.99 M
|
$22.78 M
|
| Link |
|
|
|
|
